Key Points {#FPar1}
==========

The overall incidence of adverse events (AEs) was low with multiple-dose aspirin used for several days (10.9 %), with rates comparable with those of placebo (12.4 %).A trend towards an increased risk of gastrointestinal AEs was observed with aspirin relative to placebo, with incidences of 7.4 and 5.4 %, respectively.There were no reports of serious gastrointestinal complications such as bleeding, perforation, or ulceration.

Background {#Sec1}
==========

Aspirin (acetylsalicylic acid) is one of the most commonly used over-the-counter (OTC) drugs in the world, and is used for acute self-treatment of symptoms of pain, fever, or the common cold \[[@CR1]--[@CR3]\]. The recommended OTC dose for these indications is generally 500--1000 mg repeated at 4- to 8-h intervals, and is not to exceed 3000 or 4000 mg/day, depending on country regulations. Treatment in this setting is typically short-term (mostly 3--5 days), with the exact duration of therapy dependent on local country regulations and the indication.

At OTC analgesic doses, aspirin behaves as a traditional non-selective non-steroidal anti-inflammatory drug (NSAID), in that it inhibits both cyclo-oxygenase (COX)-1 and COX-2 enzymes \[[@CR4]\]. This non-selective COX inhibition is tied to many of the adverse events (AEs) commonly associated with this class of medication. Serious gastrointestinal complications such as perforations, ulcers, or bleeding have rarely been reported with short-term or single-dose studies using OTC doses of aspirin \[[@CR5], [@CR6]\]. However, more minor gastrointestinal complaints (i.e., dyspepsia) are also of concern, as their occurrence often leads to avoidance of appropriate treatment by the patient.

Data characterizing the safety profile of OTC aspirin when used within recommended dose and short-term duration parameters are quite limited. Observational studies may not distinguish between short- and long-term OTC use, may not specify the exact doses administered, and in some cases OTC data are not captured at all. This discrepancy is important when considering differences regarding the indication, duration of therapy, and population taking prescription or long-term OTC drugs versus short-term OTC use. As a result, the increased risk of ulcers, bleeding, perforations, or other serious gastrointestinal complications associated with long-term NSAID use may not accurately represent the magnitude of risk when these drugs are used as directed in the OTC setting.

This notion is supported by limited data, existing largely in the form of single-dose and very short-term use studies \[[@CR5]--[@CR8]\]. In performing the current meta-analysis we sought to characterize the safety and tolerability of multiple high OTC doses of aspirin, used over several days for the symptomatic treatment of acute pain, fever, or the common cold.

Methods {#Sec2}
=======

We conducted a descriptive, integrated safety meta-analysis utilizing individual patient data obtained from Bayer AG (Leverkusen, Germany)-sponsored studies conducted to May 2015, in which aspirin was evaluated in a clinical trial setting and adequate documentation of AE reporting was available. Studies qualified for analysis if they met the following criteria: (1) contained a treatment arm with patients receiving aspirin monotherapy at doses ≥2000 mg/day for ≥3 days; and (2) were conducted in a randomized, placebo-controlled, parallel-group design. Of 87 clinical trials identified within the Bayer study data pool and conducted between 1987 and 2012, three satisfied all requirements and were included in the safety analysis. All three studies were designed with active and placebo comparators, and two contained an aspirin plus pseudoephedrine arm. However, only the aspirin monotherapy and placebo arms of each study were evaluated. Details of the aspirin treatment regimens administered in each study are shown in Table [1](#Tab1){ref-type="table"}. In general, daily doses of aspirin were between 1000 and 3000 mg for a duration of 3--5 days.Table 1Characteristics of the studies included in the meta-analysisCharacteristicStudy 1Study 2Study 3Study designRandomized, double-blind, placebo-controlled, parallelRandomized, double-blind, placebo-controlled, parallelRandomized, double-blind, placebo-controlled, parallelClinical phaseIIIIIIIIINumber of centers68121CountriesItaly, Poland, Slovakia, and USAGermany and UKUKIndicationAcute sore throatAcute lower back painAcute sore throat and/or headacheDosage1000 mg tid for 3 days; daily dose 3000 mg1000 mg tid prn for 5 days; daily dose 3000 mg maximum1000 mg bid or tid on day 1 and 1000 mg tid on days 2 and 3; daily dose 3000 mg maximumTreatment arms (safety set)Aspirin (*n* = 250)\
Placebo (*n* = 262)\
Aspirin/pseudoephedrine (*n* = 253)\
Pseudoephedrine (*n* = 251)Aspirin (*n* = 112)\
Placebo (*n* = 116)\
Ibuprofen (*n* = 109)Aspirin (*n* = 240)\
Placebo (*n* = 121)\
Aspirin/pseudoephedrine (*n* = 235)\
Pseudoephedrine (*n* = 237)Patients included in the analysisAspirin (*n* = 149)\
Placebo (*n* = 196)Aspirin (*n* = 54)\
Placebo (*n* = 69)Aspirin (*n* = 230)\
Placebo (*n* = 121)Subject sexMale: 44 %\
Female: 56 %Male: 53 %\
Female: 47 %Male: 29 %\
Female: 71 %Age (years) Mean (range)36.6 (18--65)46.0 (17--81)20.1 (18--39) Median35.046.020.0*bid* twice daily, *prn* as needed, *tid* three times daily

The endpoints of interest were patient-reported AEs. AEs of interest were chosen based on previous knowledge of the safety profile of aspirin and NSAID class-specific AEs. *Medical Dictionary for Regulatory Activities* (MedDRA^®^) codes (version 18.0) were used to identify these events within the data pool according to either standardized MedDRA^®^ queries (SMQs) or selected MedDRA^®^ preferred terms (PTs), high-level terms (HLTs), high-level group terms (HLGTs), or system organ classes (SOCs). Of the AEs, the gastrointestinal SOC and its related PTs, the combination of the gastrointestinal disorders heartburn, nausea, vomiting, and abdominal pain was of major interest for this analysis because their occurrence often leads to avoidance of appropriate treatment by the patient. Another area of interest was the serious events gastrointestinal hemorrhage, gastrointestinal ulceration, and gastrointestinal perforation.

Data management and statistical evaluation were performed using the SAS^®^ software package version 9.3 (SAS Institute, Cary, NC, USA). The target SAS^®^ database structure was based on agreement between Bayer AG (Leverkusen, Germany) and the M.A.R.C.O. Institute for Clinical Research and Statistics (Düsseldorf, Germany). Bayer provided SAS^®^ datasets for the studies, which were transformed into the target database structure using SAS^®^ modification programs. Information derived from the clinical study reports and listings (i.e., study title, design, blinding, randomization, dosing, AE reporting) was integrated into the target database. Quality control checks were in place at each data management step. Checks included double data entry and standard validation of statistical programs and data entry including review by a second programmer. The statistical analysis was exploratory in nature and based on available data.

Estimated incidence rates were presented for overall AEs, SOCs, and PTs, and events within each of these categories were categorized by intensity (mild, moderate, severe) for both the aspirin and placebo groups. An analysis of odds ratios (ORs) and risk differences (RDs) of aspirin versus placebo was performed.

Results {#Sec3}
=======

The data pool used for the meta-analysis consisted of a total of 819 subjects; 433 subjects received aspirin, 386 received placebo. All studies were multiple-dose studies evaluating the efficacy of aspirin versus placebo in the short-term treatment of sore throat, headache, or lower back pain. An overview of the individual study characteristics is provided in Table [1](#Tab1){ref-type="table"}.

Patient-reported AEs of the individuals included in the studies were analyzed. The current study compared the safety of aspirin monotherapy versus placebo and, therefore, although the individual studies were each designed with active and placebo comparators, only the aspirin monotherapy and placebo arms were included in the meta-analysis. Subject demographics for both meta-analysis treatment groups are described in further detail in Table [2](#Tab2){ref-type="table"}. With the exception of age and sex, baseline characteristics were generally comparable between the groups. The majority of patients in the aspirin group received a median dose of 3000 mg/day for 3 days (*n* = 372; 86 %). The remaining patients (*n* = 62; 14 %) received 2500 or 3000 mg/day for 4--6 days. The duration of aspirin exposure was greatest for the low back pain study (up to 6 days) compared with 3 or 4 days for sore throat and headache. The overall median total exposure to aspirin per patient was 8000 mg.Table 2Subject demographics of the study populationDemographicAspirin (*N* = 433)Placebo (*N* = 386)Total (*N* = 819)Sex \[*n* (%)\] Men151 (34.9)167 (43.3)318 (38.8) Women282 (65.1)219 (56.7)501 (61.2)Race \[*n* (%)\] Caucasian423 (97.7)375 (97.2)798 (97.4) Black1 (0.2)2 (0.5)3 (0.4) Asian6 (1.4)5 (1.3)11 (1.3) Other3 (0.7)4 (1.0)7 (0.9)Age (years) Mean (SD)29.1 (13.16)33.0 (14.16)30.9 (13.76) Range18--8117--7717--81 Median22.028.525.0Height (cm) Mean (SD)169.6 (9.48)170.6 (9.24)170.1 (9.37) Range147--203152--201147--203Weight (kg) Mean (SD)69.94 (13.57)71.06 (13.94)70.47 (13.75) Range42.0--121.445.0--120.042.0--121.4BMI (kg/m^2^) Mean (SD)24.23 (3.806)24.29 (3.530)24.26 (3.676) Range16.8--45.116.5--36.216.5--45.1*BMI* body mass index, *SD* standard deviation

Overall, the AE incidences were comparable between the aspirin (10.9 %) and placebo groups (12.4 %) \[OR: 0.86 (95 % confidence interval \[CI\] 0.56, 1.34); RD: −1.49 (95 % CI −6.01, 3.03)\]. Reported events were mostly mild to moderate in nature (Table [3](#Tab3){ref-type="table"}). One serious AE occurred in the aspirin group (non-cardiac chest pain), but this was determined to be unrelated to study drug. One patient, also in the aspirin group, discontinued treatment due to a skin rash that developed following 3 days of aspirin therapy and which was therefore classified as an adverse drug reaction.Table 3Incidences, odds ratios, and risk differences for adverse eventsEventResponse/treatedOdds ratio (95 % CI)Risk difference (95 % CI)Aspirin \[*N* (%)\]Placebo \[*N* (%)\]Adverse events47/433 (10.9)48/386 (12.4)0.86 (0.56, 1.34)−1.49 (−6.01, 3.03)Mild intensity18 (4.2)24 (6.2)n.c.n.c.Moderate intensity19 (4.4)16 (4.1)n.c.n.c.Severe intensity10 (2.3)8 (2.1)n.c.n.c.Gastrointestinal adverse events32/433 (7.4)21/386 (5.4)1.41 (0.78, 2.54)2.00 (−1.35, 5.35)Dyspepsia5/433 (1.2)1/386 (0.3)5.14 (0.60, 44.25)1.01 (−0.17, 2.19)Combined heartburn, nausea, vomiting, and abdominal pain27/433 (6.2)17/386 (4.4)1.43 (0.76, 2.73)1.78 (−1.33, 4.89)Headache6/433 (1.4)13/386 (3.4)0.45 (0.17, 1.23)−1.74 (−3.88, 0.41)Dizziness4/433 (0.9)4/386 (1.0)1.04 (0.26, 4.20)0.04 (−1.40, 1.49)Tinnitus3/203 (1.5)0/265 (0.0)36.10 (0.10, 13,705)1.48 (−0.18, 3.13)Abdominal pain3/379 (0.8)2/317 (0.6)1.71 (0.27, 10.82)0.38 (−0.89, 1.64)*CI* confidence interval; *n.c.* not calculated

Gastrointestinal AEs were more common in subjects treated with aspirin (7.4 %) than placebo (5.4 %). Though this difference did not meet statistical significance, a trend towards higher risk was observed with aspirin use compared with placebo \[OR: 1.41 (95 % CI 0.78, 2.54); RD: 2.00 (95 % CI −1.35, 5.35)\]. The gastrointestinal PTs heartburn, nausea, vomiting, and abdominal pain are of major importance for the tolerability of aspirin \[[@CR5], [@CR6]\]. The incidence of their combination was higher in the aspirin group than in the placebo group (6.2 vs. 4.4 %), but differences did not reach statistical significance. However, there was again a trend towards an increased risk for aspirin \[OR: 1.43 (95 % CI 0.76, 2.73); RD: 1.78 (95 % CI −1.33, 4.89)\]. The same higher incidence in the aspirin group was observed for the PT dyspepsia (aspirin 1.2 %, placebo 0.3 %), but it had a high OR (5.14) with a very broad 95 % CI (0.60, 44.25), indicating little precision due to a limited number of events. Incidences and ORs calculated for headache, dizziness, tinnitus, and abdominal pain showed no additional risk associated with aspirin compared with placebo (Table [3](#Tab3){ref-type="table"}). There were no reports of serious gastrointestinal complications such as perforations, ulcers, and bleeding, as was the case with impaired hearing ability, mental confusion, cerebral hemorrhage, and hypersensitivity reactions.

Discussion {#Sec4}
==========

The findings from the current individual patient data meta-analysis appear to support the safety and tolerability of the use of multiple high-dose treatment with aspirin in the self-medication setting for the acute treatment of pain, fever, or the common cold in an otherwise healthy and young population. Aspirin use was not associated with a significant increase in the risk of overall or gastrointestinal-specific AEs. In fact, ORs and RDs for the comparison of aspirin and placebo were not statistically significant for any of the safety endpoints. Gastrointestinal AEs occurred at a low rate overall, and, importantly, no cases of serious gastrointestinal complications (i.e., perforation, ulceration, or bleeding) were reported. However, the generalizability of these findings to a broader population is inappropriate as the data used for this meta-analysis were sourced from a limited pool of qualifying Bayer-sponsored studies, which comprised healthy, younger adult subjects at low risk of gastrointestinal events. This could have contributed to the low incidence of gastrointestinal AEs observed in both treatment groups.

This multiple-dose meta-analysis enhances the existing safety profile of OTC aspirin used for non-cardiac indications, as the large majority of existing data are derived from very short-term, mostly single-dose studies. It must be emphasized, however, that though the doses and durations of aspirin treatment included in this study extend beyond single-dose administration, they still reflect short-term treatment in the OTC setting. Therefore, conclusions drawn from these data are not valid in the context of long-term use, or use that lies outside of the treatment algorithms outlined in these studies.

The results of the current analysis are generally in agreement with findings from four previous meta-analyses and one randomized controlled clinical trial examining the safety of acute OTC aspirin use. Meta-analyses by Lanas et al. \[[@CR5]\], Edwards et al. \[[@CR7]\], and Steiner and Voelker \[[@CR8]\] consisted mostly of single-dose data, while the current analysis, Baron et al. \[[@CR6]\], and the PAIN \[Paracetamol, Aspirin and Ibuprofen New tolerability\] study \[[@CR9]\] examined higher OTC doses used for a longer duration (3--10 days). In order to bring the current data into perspective, Table [4](#Tab4){ref-type="table"} shows the incidences, ORs, RDs, and relative risks of overall and gastrointestinal AEs.Table 4Comparison of studies investigating the safety and tolerability of aspirinCurrent meta-analysisLanas et al. \[[@CR5]\] meta-analysisEdwards et al. \[[@CR7]\] meta-analysisSteiner and Voelker \[[@CR8]\] meta-analysisBaron et al. \[[@CR6]\] meta-analysisPAIN study RCT \[[@CR9]\]Year201520111999200920131999Number of studies/patients3/81967/13,22272/65509/285278/19,8298633 patientsPatient population includedPatients with symptomatic upper respiratory tract infection or acute lower back painPatients with pain, fever, or common coldPatients with post-operative painPatients with acute migraine attacks, episodic tension-type headache, and dental painPatients on ASA who experienced a GI eventPatients with common mild to moderate painTreatmentsDaily ASA dose of 2000 mg taken for a minimum duration of 3 days and up to 6 daysMostly single ASA doses of ≥325 mg/daySingle-dose ASA 600/650, 1000, or 1200 mgSingle doses of ASA 1000 mgASA dose between 325 and 4000 mg/day with a treatment duration of up to 10 daysASA up to 3 g/day, PAR up to 3 g/day, or IBU up to 1.2 g/day for up to 7 daysSafety endpointPatient-reported AEsPatient-reported AEsPatient-reported AEsPatient-reported AEsPatient-reported AEsPatient-reported AEsResults \[95 % CI\] All AEsASA 10.9 %\
Placebo 12.4 %\
OR 0.86 \[0.56, 1.34\]\
RD −1.49 \[−6.01, 3.03\]ASA 15.2 %\
Placebo 15.5 %\
OR 1.1 \[0.96, 1.2\]\
RD 1.0 \[−0.5, 2.5\]ASA all doses 12.0 %\
Placebo 10.0 %\
RR 1.3 \[0.9, 1.5\]\
ASA 600/650 mg 13.0 %\
Placebo 11.0 %\
RR 1.2 \[1.03, 1.4\]ASA 14.9 %\
Placebo 11.1 %\
RR 1.3 \[1.1, 1.6\]Not availableASA 18.5 %\
IBU 13.4 %\
PAR 13.8 % GI AEsASA 7.4 %\
Placebo 5.4 %\
OR 1.41 \[0.78, 2.54\]\
RD 2.00 \[−1.35, 5.35\]ASA 9.9 %\
Placebo 9.0 %\
OR 1.3 \[1.1, 1.5\]\
RD 2.1 \[0.9, 3.3\]ASA 600/650 mg 3.7 %\
Placebo 1.1 %\
RR 2.5 \[1.2, 5.1\]ASA 5.9 %\
Placebo 3.5 %\
RR 1.7 \[1.2, 2.4\]ASA 9.4 %\
Placebo 4.2 %\
OR 2.12 \[0.95, 4.76\]ASA 7.1 %\
IBU 4.0 %\
PAR 5.3 %*AEs* adverse events, *ASA* aspirin, *CI* confidence interval, *GI* gastrointestinal, *IBU* ibuprofen, *OR* odds ratio, *PAR* paracetamol, *RCT* randomized controlled trial, *RD* risk difference, *RR* relative risk

Among the meta-analyses, the incidence of aspirin versus placebo AEs is consistently in the range of 10--15 %, and the AEs reported in the current analysis were comparable between the aspirin and placebo groups (10.9 vs. 12.4 %). Lanas et al. \[[@CR5]\] observed a similar pattern (15.2 vs. 15.5 %), although these AE rates appear to be higher than those seen in our study. This could be due, in part, to the substantially larger population in the Lanas et al. \[[@CR5]\] analysis. The Edwards et al. \[[@CR7]\] and Steiner and Voelker \[[@CR8]\] analyses reported AE incidences within a similar range (13 vs. 11 % and 14.9 vs. 11.1 %, respectively) to those seen in Lanas et al. \[[@CR5]\] and the current study.

The incidence of gastrointestinal AEs is generally in the range of 6--10 % for aspirin (including the PAIN study) and 4--9 % for placebo, showing a substantial overlap of the two ranges. The incidence of gastrointestinal AEs was higher in the aspirin than in the placebo group (7.4 vs. 5.4 %) in the current analysis, a pattern also seen in the study by Lanas et al. \[[@CR5]\] (9.9 vs. 9.0 %), although the increase in risk was significant in that study (OR 1.3; 95 % CI 1.1, 1.5). The Baron et al. \[[@CR6]\] meta-analysis also observed a higher incidence of overall gastrointestinal risk with aspirin use than with placebo, but reported no serious AEs.

The AE of interest, dyspepsia, was associated with an OR of 5.14 in the current study. However, there is a very wide CI associated with this estimate (0.6, 44), suggesting a substantial level of variability in the data due to the low number of cases (sparse data scenario), but also a trend towards significance due to the large right shift of the CI. Yet, upon examining the data from the Lanas et al. \[[@CR5]\] analysis, it becomes apparent that this finding in our study should not be disregarded: Lanas et al. \[[@CR5]\] found a significantly higher risk of dyspepsia in patients taking aspirin. Again, the difference in population size could have contributed to the discrepancy in the results observed for these two studies.

Taken together, these results suggest that the safety and tolerability seen with short-term OTC aspirin (used according to the directions on the label) extends to multiple-day use (not to exceed 3--10 days depending on local country regulations and indication) in a population with low gastrointestinal risk. It must be noted, however, that this observation may not apply to higher-risk patients such as the elderly or those with a history of ulcers, and is only representative of an acute clinical scenario appropriate for self-treatment. No previously unknown risks, which would change the overall benefit--risk ratio of aspirin for pain and fever, have been detected in the current or previous analyses and studies. Furthermore, serious AEs such as perforations, ulcers, and bleeding have not been observed in these clinical investigations.

The frequency of AEs was quite low in the current analysis and the meta-analyses discussed here. This may in part be due to the population studied, as subjects were typically young and otherwise healthy. This probably does not mirror the patient populations from several observational studies that have suggested that aspirin taken for pain, fever, or the common cold is associated with an increased risk of major gastrointestinal complications, similar to other non-selective NSAIDs \[[@CR10]--[@CR12]\]. A recent large population-based study found that those on prescription NSAIDs were generally older, more frequently overweight, and had more co-morbidities than their OTC NSAID-using counterparts \[[@CR3]\]. While there is a well-known association between long-term NSAID use, the above-mentioned risk factors, and an increased likelihood of developing serious gastrointestinal complications, caution must be exercised in drawing generalized conclusions from data obtained specifically from OTC or prescription-strength NSAID use, as these data may not be applicable to a broader or disparate population.

ORs and RDs for the comparison of aspirin and placebo were not statistically significant for any of the safety endpoints of interest. However, interpretation of these results must be accompanied by a thorough inspection of the limitations of the analysis. First, the analysis population was young and generally healthy. Furthermore, the total sample size is limited. A low number of events may have impaired the sensitivity of the analysis to detect a difference between aspirin and placebo. In this situation, a lack of statistical significance should not be considered synonymous with the conclusion that aspirin does not increase the risk of gastrointestinal AEs, particularly for endpoints for which other studies have shown a trend for such an association. The studies included in the analysis did not prohibit the use of gastroprotective agents, though concomitant medications were documented and subjects were generally healthy.

Conclusions {#Sec5}
===========

This analysis shows that OTC aspirin taken at doses of 2500--3000 mg/day over 3--6 days is well-tolerated when taken as directed for the treatment of acute pain, fever, and the common cold. Though the incidence of gastrointestinal AEs was elevated in aspirin users compared with placebo users, the risk of these AEs was not statistically significantly different, and there were no reports of serious gastrointestinal complications in either of the groups. However, it is critical that the results of this study should be interpreted within the full context of the limited sample size. Therefore, firm conclusions cannot be drawn based on these data alone.
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